Literature DB >> 20465910

Supratentorial Brain AVM Embolization with Onyx-18 and Post-Embolization Management. A Single-Center Experience.

J W Pan1, H J Zhou, R Y Zhan, S Wan, M Yan, W J Fan, Z X Wu, S S Zheng.   

Abstract

SUMMARY: Onyx is increasingly used in endovascular therapy of intracranial arteriovenous malformations (AVMs). However, the embolic effect and post-embolization management are still under discussion. We report our experience in the treatment of supratentorial brain arteriovenous malformations (SBAVMs) with Onyx and discuss post-embolic management. From June 2006 to July 2008, 20 patients with SBAVM were embolized with Onyx. There were 14 men and six women ranging from 14 to 64 years of age (mean 38.3 years). Initial symptoms included spontaneous hemorrhage (n=12), headaches (n=4), seizure (n=3) and incidentally disclosed after head trauma (n=1). After the endovascular procedure, all had subsequent treatment (follow-up angiogram, stereotactic radiosurgery or microsurgery) according to the obliteration degree. At angiography, seven patients (35%, 7/20) were completely obliterated (over 95% closure) after embolization while one suffered a small subarachnoid hemorrhage without permanent clinical sequelae. Four patients (20%, 4/20) were subtotally obliterated (over 80% closure), one patient who suffered severe cerebral edema after embolization underwent decompressive craniectomy, two patients had additional radiosurgery and one patient had follow-up angiogram. Nine patients (45%, 9/20) were partially obliterated (20-80% closure), five patients had additional surgery, two patients had additional radiosurgery and two patients had follow-up angiogram (one patient had intraventricular hemorrhage three months after embolization). Of all 20 AVMs, an average of 2.2 ml Onyx was used per patient and average volume reduction was 80% (range, 30%-99%). Onyx is suitable for embolization of SBAVMs because of its diffuse controllable properties. We suggest clinical follow-up after complete obliteration, additional radiosurgery or angiographic follow-up after subtotal obliteration and additional surgery after partially obliteration. More cases with long-term follow-up are needed to evaluate the long-term prognosis of our post-embolization management.

Entities:  

Year:  2009        PMID: 20465910      PMCID: PMC3299373          DOI: 10.1177/159101990901500304

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  14 in total

1.  Complete obliteration of intracranial arteriovenous malformation with endovascular cyanoacrylate embolization: initial success and rate of permanent cure.

Authors:  Simon C H Yu; Michael S Y Chan; Joseph M K Lam; Patrick H T Tam; Wai S Poon
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

2.  Endovascular Treatment of Cerebral AVM: Our Experience with Onyx.

Authors:  A Pérez-Higueras; R Rossi López; D Quiñones Tapia
Journal:  Interv Neuroradiol       Date:  2005-10-27       Impact factor: 1.610

3.  Combined therapy of cerebral arteriovenous malformations: histological differences between a non-adhesive liquid embolic agent and n-butyl 2-cyanoacrylate (NBCA).

Authors:  F Duffner; R Ritz; A Bornemann; D Freudenstein; H Wiendl; R Siekmann
Journal:  Clin Neuropathol       Date:  2002 Jan-Feb       Impact factor: 1.368

4.  Brain AVM embolization with Onyx.

Authors:  W J van Rooij; M Sluzewski; G N Beute
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

5.  Embolization of arteriovenous malformations with Onyx: clinicopathological experience in 23 patients.

Authors:  R Jahan; Y Murayama; Y P Gobin; G R Duckwiler; H V Vinters; F Viñuela
Journal:  Neurosurgery       Date:  2001-05       Impact factor: 4.654

6.  Endovascular treatment of intracranial arteriovenous malformations with onyx: technical aspects.

Authors:  W Weber; B Kis; R Siekmann; D Kuehne
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

7.  Preoperative embolization of intracranial arteriovenous malformations with Onyx.

Authors:  Werner Weber; Bernhard Kis; Ralf Siekmann; Paul Jans; Rudolf Laumer; Dietmar Kühne
Journal:  Neurosurgery       Date:  2007-08       Impact factor: 4.654

8.  Nonadhesive liquid embolic agent for cerebral arteriovenous malformations: preliminary histopathological studies in swine rete mirabile.

Authors:  Y Murayama; F Viñuela; A Ulhoa; Y Akiba; G R Duckwiler; Y P Gobin; H V Vinters; R J Greff
Journal:  Neurosurgery       Date:  1998-11       Impact factor: 4.654

9.  Curative embolization of cerebral arteriovenous malformations (AVMs) with Onyx in 101 patients.

Authors:  Vasilios Katsaridis; Chrysanthi Papagiannaki; Enrico Aimar
Journal:  Neuroradiology       Date:  2008-04-12       Impact factor: 2.804

10.  [Clinical experience of 70 cases of cerebral arteriovenous malformations embolization with Onyx, a novel liquid embolic agent].

Authors:  Dong-Lei Song; Bing Leng; Bin Xu; Qi-Hong Wang; Xian-Cheng Chen; Liang-Fu Zhou
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2007-02-15
View more
  5 in total

1.  Angioarchitectural characteristics associated with complications of embolization in supratentorial brain arteriovenous malformation.

Authors:  J Pan; H He; L Feng; F Viñuela; Z Wu; R Zhan
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-25       Impact factor: 3.825

2.  Focus on the target: Angiographic features of the fistulous point and prognosis of transvenous embolization of cavernous sinus dural arteriovenous fistula.

Authors:  Hui Guo; QianKun Yin; Peng Liu; Ning Guan; Xiaochuan Huo; Youxiang Li
Journal:  Interv Neuroradiol       Date:  2018-01-19       Impact factor: 1.610

3.  Combined treatment of brain AVMs with use of Onyx embolization followed by radiosurgery.

Authors:  L Pierot; K Kadziolka; F Litré; P Rousseaux
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-07       Impact factor: 3.825

4.  Successful use of Onyx® for transcatheter arterial embolization of a scrotal arteriovenous malformation refractory to traditional embolic agents.

Authors:  Ryan Key; Thomas Bishop
Journal:  Radiol Case Rep       Date:  2015-11-06

5.  Embolization with ethylene vinyl alcohol copolymer (Onyx®) for peripheral hemostatic and non-hemostatic applications: a feasibility and safety study.

Authors:  Romaric Né; Olivier Chevallier; Nicolas Falvo; Olivier Facy; Pierre-Emmanuel Berthod; Christophe Galland; Sophie Gehin; Marco Midulla; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2018-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.